Clinical Trial Update: Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ceftolozane/tazobactam plus metronidazole to meropenem for complicated intra-abdominal infections has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Intra-abdominal Infections

Drugs mentioned

• Ceftolozane/Tazobactam (ceftolozane/tazobactam)
• METRONIDAZOLE (Metronidazole)
• Meropenem (Meropenem)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Complicated Intra-abdominal Infections | Phase 3 | Status: COMPLETED | Results posted: 2021-10-22